Virtual Library
Start Your Search
J.D. Andrade-Neto
Author of
-
+
P3.08 - Poster Session/ Thymoma, Mesothelioma and Other Thoracic Malignancies (ID 226)
- Event: WCLC 2015
- Type: Poster
- Track: Thymoma, Mesothelioma and Other Thoracic Malignancies
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.08-017 - Quality of Life Impact and Adverse Events after Pleurodesis in Patients with Recurrent Malignant Pleural Effusion (ID 2510)
09:30 - 09:30 | Author(s): J.D. Andrade-Neto
- Abstract
Background:
Even though pleurodesis is the gold-standard procedure to manage recurrent malignant pleural effusion (RMPE), little is known of its impact on the quality of life (QOL), adverse events, and systemic inflammatory consequences. Our main objective was to evaluate the impact of pleurodesis on the QOL of patients with RMPE and the adverse events related to the procedure. The secondary objectives were to evaluate systemic consequences of pleurodesis and to identify predictors of QOL improvement after pleurodesis.
Methods:
Retrospective study including data from patients who underwent pleurodesis from 2005 to 2014 at our Institution. QOL was measured through WHOQoL-Bref instrument, pain visual analog scale, and British Medical Research Council dyspnea scale. Adverse events were systematically registered and classified according to the NCI–CTCAEV.4.0. Blood tests were collected before, 2, 5, and 10 days after the pleurodesis. To compare continuous variables we used paired-T test or Wilcoxon test. To find predictors we built linear regression models. We considered as significant tests which p<0.05.
Results:
257 patients (77% female) with mean age of 69 years-old(± 13.01) were included. The most frequent primary malignancies were breast cancer (56%) and lung cancer (25%). The sclerosing agents used were talc (38%), silver nitrate (36%), and iodopovidone (25%). Clinical recurrence was observed in 8% of the patients and mean survival was 8 months. The physical domain of QOL as well as pain and dyspnea scores were the most abnormal results at baseline and were also the variables which improved the most 30 days after the procedure (p<0.001 for all 3 parameters). Female gender, low pleural fluid lymphocytes count, and the use of silver nitrate were associated with QOL improvement. Adverse events occurred in 43% of the patients, and in 16.3% we observed severe events (Grade 3 or higher). Hypoxia, renal failure, and pain were the most frequent. We observed significant variation in the following blood tests: C-Reactive Protein (rise), hemoglobin (decrease), platelets (rise), alkaline phosphatase (rise).
Conclusion:
Pleurodesis is associated with improvement of the QOL of patients with RMPE; nevertheless, it is also associated with high number of adverse events and systemic metabolic effects.
